

Supplementary table. Hazard ratio of baseline characteristics of patients with or without dupilumab-associated conjunctivitis

Variables (class cut-off)	Number of patients with or without conjunctivitis		Hazard Ratio	95% confidence interval	
	W	W/O			
Ageclass	>33	13	18	0.99	0.47 - 2.09
	<=33	16	25	Reference	
Sex	M	20	23	1.59	0.72 - 3.49
	F	9	20	Reference	
IgE Total IgE levels, KUA/L ^s	>3637	9	2	3.15	1.2 - 8.26
	100-3637	12	29	0.68	0.28 - 1.66
	<=100	8	12	Reference	
Blood eosinophil count on log scale, cells/L ^{ss}	>350	17	11	3.99	1.71 - 9.29
	<=350	12	32	Reference	
POEM score	>24	4	7	0,67	0.19 - 2.37
	>16 - <=24	9	20	0.58	0.21 - 1.62
	>8 - <=16	10	9	1.13	0.41 - 3.12
	<=8	6	7	Reference	
Peak score on NRS for sleep	>8	11	14	1.14	0.53 - 2.44
	<=8	18	29	Reference	
Peak score on NRS for pruritus	>8	17	18	1.57	0.75 - 3.29
	<=8	12	25	Reference	
SCORAD score	>76.6	9	5	2.29	1.04 - 5.05
	<=76,6	20	38	Reference	
EASI score	>37.7	5	7	1.12	0.43 - 2.93
	<=37.7	24	36	Reference	
DLQI score	>20	4	12	0.55	0.1 - 3.03
	>10 - <=20	20	25	0.26	0.26 - 4.78
	>6 - <=10	3	3	0.22	0.22 - 7.78
	0 - 6	2	3	Reference	
Family history of allergic conjunctivitis	Y	5	2	2.77	1.05 - 7.29
	N	24	41	Reference	

History of conjunctivitis	Y	27	10	21.31	5.03 - 90.26
	N	2	33	Reference	
History of infective conjunctivitis	Y	4	5	1.25	0.43 - 3.58
	N	25	38	Reference	
Other atopic conditions	Y	16	12	2.51	1.21 - 5.24
	N	13	31	Reference	

Abbreviation: Dermatology Life Quality Index (DLQI), EASI=Eczema Area and Severity Index (EASI), Hazard Ratio (HR), Numerical Rating Scale (NRS), Patient-Oriented Eczema Measure (POEM), SCORing Atopic Dermatitis (SCORAD). [§] Performed in 90 patients. ^{§§} Performed in 89 patients.

Accepted Article